益佰制药
(600594)
| 流通市值：26.85亿 | | | 总市值：26.85亿 |
| 流通股本：7.92亿 | | | 总股本：7.92亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,713,840,317.37 | 1,168,191,423.5 | 572,646,100.11 | 2,820,561,015 |
| 营业收入 | 1,713,840,317.37 | 1,168,191,423.5 | 572,646,100.11 | 2,820,561,015 |
| 二、营业总成本 | 1,842,847,294.11 | 1,265,385,630.58 | 635,203,702.04 | 2,621,425,841.6 |
| 营业成本 | 647,908,117.57 | 438,677,697.07 | 225,763,334.16 | 861,096,285.77 |
| 税金及附加 | 25,717,399.32 | 16,528,932.01 | 9,499,480.87 | 42,658,654.5 |
| 销售费用 | 823,502,438.57 | 581,646,259.15 | 292,185,359.66 | 1,238,440,637.53 |
| 管理费用 | 250,408,193.03 | 163,906,482.89 | 76,890,947.91 | 351,478,112.98 |
| 研发费用 | 79,177,945.47 | 52,148,931.55 | 22,795,778.94 | 112,147,338 |
| 财务费用 | 16,133,200.15 | 12,477,327.91 | 8,068,800.5 | 15,604,812.82 |
| 其中:利息费用 | 21,271,856.68 | 16,042,041.77 | 9,611,697.66 | 21,642,251.59 |
| 其中:利息收入 | 5,715,702.93 | 4,186,558.75 | 2,054,991.81 | 7,070,673.2 |
| 加:投资收益 | 146,759.24 | 150,246.77 | 58,699.85 | 28,699.17 |
| 资产处置收益 | 646,711.69 | 89,603.73 | 89,603.73 | 16,639.11 |
| 资产减值损失(新) | -48,293,610.56 | -18,277,192.4 | -10,322,080.01 | -94,051,202.52 |
| 信用减值损失(新) | -2,615,865.64 | -1,624,225.36 | 45,716.78 | 3,696,796.49 |
| 其他收益 | 15,651,499.98 | 10,423,555.42 | 4,954,499.44 | 28,531,850.86 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -163,471,482.03 | -106,432,218.92 | -67,731,162.14 | 137,357,956.51 |
| 加:营业外收入 | 649,810.26 | 545,438.33 | 29,426.67 | 4,793,116.4 |
| 减:营业外支出 | 10,944,727.49 | 8,137,762.82 | 2,063,978.25 | 9,830,368.27 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -173,766,399.26 | -114,024,543.41 | -69,765,713.72 | 132,320,704.64 |
| 减:所得税费用 | 475,420.6 | -3,050,559.84 | 1,646,069.06 | 40,963,583.51 |
| 六、净利润 | -174,241,819.86 | -110,973,983.57 | -71,411,782.78 | 91,357,121.13 |
| 持续经营净利润 | -174,241,819.86 | -110,973,983.57 | -71,411,782.78 | 91,357,121.13 |
| 归属于母公司股东的净利润 | -169,151,279.27 | -106,493,434.06 | -68,454,808.45 | 103,399,049.91 |
| 少数股东损益 | -5,090,540.59 | -4,480,549.51 | -2,956,974.33 | -12,041,928.78 |
| (一)基本每股收益 | -0.21 | -0.13 | -0.09 | 0.13 |
| (二)稀释每股收益 | -0.21 | -0.13 | -0.09 | 0.13 |
| 八、其他综合收益 | 27,008.83 | 39,540.83 | 39,540.83 | -343,624.32 |
| 归属于母公司股东的其他综合收益 | 27,008.83 | 39,540.83 | 39,540.83 | -343,624.32 |
| 九、综合收益总额 | -174,214,811.03 | -110,934,442.74 | -71,372,241.95 | 91,013,496.81 |
| 归属于母公司股东的综合收益总额 | -169,124,270.44 | -106,453,893.23 | -68,415,267.62 | 103,055,425.59 |
| 归属于少数股东的综合收益总额 | -5,090,540.59 | -4,480,549.51 | -2,956,974.33 | -12,041,928.78 |
| 公告日期 | 2024-10-26 | 2024-08-24 | 2024-04-19 | 2024-04-19 |
| 审计意见(境内) | | | | 标准无保留意见 |